Slotnik Capital LLC Acquires 16,000 Shares of Catalent, Inc. (NYSE:CTLT)

Slotnik Capital LLC lifted its stake in shares of Catalent, Inc. (NYSE:CTLT) by 8.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 195,500 shares of the company’s stock after buying an additional 16,000 shares during the quarter. Catalent makes up about 5.4% of Slotnik Capital LLC’s investment portfolio, making the stock its 6th largest holding. Slotnik Capital LLC owned approximately 0.11% of Catalent worth $10,993,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Lindbrook Capital LLC raised its stake in Catalent by 79.4% during the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after buying an additional 208 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Catalent during the 2nd quarter valued at approximately $42,000. Mather Group LLC. bought a new position in Catalent during the first quarter worth $52,000. Longfellow Investment Management Co. LLC boosted its holdings in Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after purchasing an additional 305 shares during the period. Finally, GAMMA Investing LLC increased its stake in Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after purchasing an additional 212 shares during the last quarter.

Catalent Stock Performance

CTLT opened at $59.73 on Tuesday. The company has a current ratio of 2.52, a quick ratio of 1.77 and a debt-to-equity ratio of 1.35. The business’s 50 day moving average is $59.52 and its 200-day moving average is $57.24. The stock has a market cap of $10.81 billion, a PE ratio of -9.79, a price-to-earnings-growth ratio of 1.88 and a beta of 1.15. Catalent, Inc. has a twelve month low of $31.80 and a twelve month high of $61.20.

Catalent (NYSE:CTLT) last announced its earnings results on Thursday, August 29th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.13. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The firm had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.23 billion. On average, analysts predict that Catalent, Inc. will post 1.06 earnings per share for the current year.

Insider Buying and Selling

In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the firm’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the transaction, the chief executive officer now owns 177,521 shares of the company’s stock, valued at approximately $10,431,133.96. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Catalent news, CFO Matti Masanovich sold 2,993 shares of the company’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $56.74, for a total value of $169,822.82. Following the completion of the sale, the chief financial officer now directly owns 33,871 shares of the company’s stock, valued at approximately $1,921,840.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Alessandro Maselli sold 9,088 shares of the company’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the sale, the chief executive officer now directly owns 177,521 shares of the company’s stock, valued at $10,431,133.96. The disclosure for this sale can be found here. Insiders sold 13,409 shares of company stock valued at $782,923 over the last 90 days. 0.31% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on CTLT shares. StockNews.com started coverage on shares of Catalent in a report on Wednesday, September 18th. They issued a “sell” rating for the company. Barclays lifted their target price on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research note on Friday, June 28th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $63.50 target price on shares of Catalent in a report on Thursday, July 11th. Finally, William Blair reissued a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $58.08.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.